| Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial P Ponikowski, BA Kirwan, SD Anker, T McDonagh, M Dorobantu, ... The Lancet 396 (10266), 1895-1904, 2020 | 563 | 2020 |
| Valsartan for prevention of recurrent atrial fibrillation P Delise, F Bertocchi, G Maiocchi, E Geraci, E Correale, F Lombardi, ... New England Journal of Medicine 360 (16), 1606-1617, 2009 | 470 | 2009 |
| miR-579-3p controls melanoma progression and resistance to target therapy L Fattore, R Mancini, M Acunzo, G Romano, A Laganà, ME Pisanu, ... Proceedings of the National Academy of Sciences 113 (34), E5005-E5013, 2016 | 117 | 2016 |
| MicroRNAs in melanoma development and resistance to target therapy L Fattore, S Costantini, D Malpicci, CF Ruggiero, PA Ascierto, CM Croce, ... Oncotarget 8 (13), 22262, 2017 | 99 | 2017 |
| Activation of an early feedback survival loop involving phospho-ErbB3 is a general response of melanoma cells to RAF/MEK inhibition and is abrogated by anti-ErbB3 antibodies L Fattore, E Marra, ME Pisanu, A Noto, C de Vitis, F Belleudi, L Aurisicchio, ... Journal of translational medicine 11, 1-11, 2013 | 78 | 2013 |
| Early risks of death, stroke/systemic embolism, and major bleeding in patients with newly diagnosed atrial fibrillation: results from the GARFIELD-AF registry JP Bassand, S Virdone, SZ Goldhaber, AJ Camm, DA Fitzmaurice, ... Circulation 139 (6), 787-798, 2019 | 76 | 2019 |
| Inhibition of Stearoyl-CoA desaturase 1 reverts BRAF and MEK inhibition-induced selection of cancer stem cells in BRAF-mutated melanoma ME Pisanu, M Maugeri-Saccà, L Fattore, S Bruschini, C De Vitis, E Tabbì, ... Journal of Experimental & Clinical Cancer Research 37, 1-17, 2018 | 69 | 2018 |
| Reprogramming miRNAs global expression orchestrates development of drug resistance in BRAF mutated melanoma L Fattore, CF Ruggiero, ME Pisanu, D Liguoro, A Cerri, S Costantini, ... Cell Death & Differentiation 26 (7), 1267-1282, 2019 | 62 | 2019 |
| Management and 1‐year outcomes of patients with newly diagnosed atrial fibrillation and chronic kidney disease: results from the prospective GARFIELD‐AF registry S Goto, P Angchaisuksiri, JP Bassand, AJ Camm, H Dominguez, ... Journal of the American Heart Association 8 (3), e010510, 2019 | 59 | 2019 |
| Selective targeting of point-mutated KRAS through artificial microRNAs M Acunzo, G Romano, G Nigita, D Veneziano, L Fattore, A Laganà, ... Proceedings of the National Academy of Sciences 114 (21), E4203-E4212, 2017 | 50 | 2017 |
| Toxicity of aflatoxin B1 towards the vitamin D receptor (VDR) P Costanzo, A Santini, L Fattore, E Novellino, A Ritieni Food and Chemical Toxicology 76, 77-79, 2015 | 46 | 2015 |
| Single cell analysis to dissect molecular heterogeneity and disease evolution in metastatic melanoma L Fattore, CF Ruggiero, D Liguoro, R Mancini, G Ciliberto Cell death & disease 10 (11), 827, 2019 | 43 | 2019 |
| Monoclonal antibody-induced ErbB3 receptor internalization and degradation inhibits growth and migration of human melanoma cells F Belleudi, E Marra, F Mazzetta, L Fattore, MR Giovagnoli, R Mancini, ... Cell Cycle 11 (7), 1455-1467, 2012 | 41 | 2012 |
| Combination therapy with anti-ErbB3 monoclonal antibodies and EGFR TKIs potently inhibits non-small cell lung cancer A Noto, C De Vitis, G Roscilli, L Fattore, D Malpicci, E Marra, L Luberto, ... Oncotarget 4 (8), 1253, 2013 | 40 | 2013 |
| microRNA-378a-5p iS a novel positive regulator of melanoma progression MG Tupone, S D’Aguanno, M Di Martile, E Valentini, M Desideri, ... Oncogenesis 9 (2), 22, 2020 | 39 | 2020 |
| TrkB is responsible for EMT transition in malignant pleural effusions derived cultures from adenocarcinoma of the lung A Ricci*, C De Vitis*, A Noto*, L Fattore, S Mariotta, E Cherubini, G Roscilli, ... Cell cycle 12 (11), 1696-1703, 2013 | 39 | 2013 |
| Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma L Fattore, D Malpicci, E Marra, F Belleudi, A Noto, C De Vitis, ME Pisanu, ... Oncotarget 6 (28), 24823, 2015 | 33 | 2015 |
| MicroRNA-driven deregulation of cytokine expression helps development of drug resistance in metastatic melanoma L Fattore, A Sacconi, R Mancini, G Ciliberto Cytokine & Growth Factor Reviews 36, 39-48, 2017 | 28 | 2017 |
| CytoMatrix for a reliable and simple characterization of lung cancer stem cells from malignant pleural effusions S Bruschini, S di Martino, ME Pisanu, L Fattore, C De Vitis, V Laquintana, ... Journal of Cellular Physiology 235 (3), 1877-1887, 2020 | 27 | 2020 |
| ErbB3 phosphorylation as central event in adaptive resistance to targeted therapy in metastatic melanoma: early detection in CTCs during therapy and insights into regulation by … CF Ruggiero, D Malpicci, L Fattore, G Madonna, V Vanella, D Mallardo, ... Cancers 11 (10), 1425, 2019 | 26 | 2019 |
